ArticleClinical & experimental neuroimmunology2022
Guillain-Barré syndrome after coronavirus disease 2019 vaccine: A temporal association.
Article in Clinical & experimental neuroimmunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Neuromuscular diseases associated with COVID-19 vaccines: a systematic review and pooled analysis of 258 patients.BMC neurology · 2023Pooled it
- Guillain-Barré syndrome in association with COVID-19 vaccination: a systematic review.Immunologic research · 2022Pooled it
- Review
- Incidence of Guillain-Barré Syndrome (GBS) after COVID-19 Vaccination: a Systematic Review and Meta-Analysis.Maedica · 2024Review
- Cardiac and Neurological Complications Post COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series.Vaccines · 2024Review
- Guillain-Barre syndrome following COVID-19 vaccination: a study of 70 case reports.Annals of medicine and surgery (2012) · 2024Review
- Guillain-Barré Syndrome Induced by Vaccination Against COVID-19: A Systematic Review and Meta-Analysis.Cureus · 2023Review
- Guillain-Barré syndrome associated with SARS-CoV-2 vaccination: how is it different? a systematic review and individual participant data meta-analysis.Clinical and experimental vaccine research · 2023Article
- Co-VAN study: COVID-19 vaccine associated neurological diseases- an experience from an apex neurosciences centre and review of the literature.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2023Review
- Guillain-Barré Syndrome Post COVID-19 Vaccination with ChAdOx1 nCoV-19 Vaccine: A Colombian Case Report.Case reports in infectious diseases · 2023Article
- [NEUROLOGICAL MANIFESTATIONS ASSOCIATED WITH COVID-19 VACCINE].Neurologia (Barcelona, Spain) · 2022Article
- Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review.Journal of autoimmunity · 2022Review
- Short-term mortality following COVID-19 vaccination in Bologna, Italy: a one-year study.Vaccine · 2022Observational
- Dementia in a patient with autoimmune disease and hypercoagulable state worsened by COVID-19 vaccination: A case report.Annals of medicine and surgery (2012) · 2022Article
- Prognosis of Guillain-Barré Syndrome Linked to COVID-19 Vaccination.Brain sciences · 2022Article
- Guillain-Barré syndrome after coronavirus disease 2019 vaccine: A temporal association.Clinical & experimental neuroimmunology · 2022Article
- Nerve conduction studies support the classification of SARS-CoV-2 associated Guillain-Barre subtypes.Clinical & experimental neuroimmunology · 2022Article
- Response to "Nerve conduction studies support the classification of SARSCoV-2 associated Guillain-Barre subtypes".Clinical & experimental neuroimmunology · 2022Article
- CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic review.Frontiers in neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Guillain-Barré syndrome (GBS) is an acute monophasic immune-mediated polyradiculoneuropathy, preceded by gastrointestinal or respiratory infections in up to two-thirds of patients. On rare occasions, people develop GBS after vaccination, but no causal association has been proven. In the current coronavirus disease 2019 (COVID-19) pandemic, some cases have been reported associating COVID-19 vaccine with GBS. Case presentation: We report a case of a 62-year-old woman with GBS after the first dose of the Oxford/AstraZeneca vaccine against SARS-CoV-2. The symptoms started 3 weeks after the vaccine, and were characterized by ascending and progressive paresthesia in the upper and lower limbs, followed by loss of strength of the upper limbs and dysphagia for solids. The hypothesis of GBS was confirmed by clinical presentation compatible with albuminocytologic dissociation in cerebrospinal fluid and based on the Brighton criteria level 2. The treatment was a 5-day course of intravenous immunoglobulin with an improvement of symptoms. Conclusions: In the absence of other causes, the diagnosis of GBS was made, with evidence of a clear temporal association with COVID-19 vaccine. However, a cautious position is important when assigning a particular side-effect directly to a vaccine. It is important to emphasize that it is a temporal association only and the benefits of COVID-19 vaccination continue to outweigh the possible consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.